Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.

Autor: Hvid LG; Exercise Biology, Department of Public Health, Aarhus University, Dalgas Avenue 4, Aarhus, Denmark. lhvid@ph.au.dk.; The Danish MS Hospitals, Ry and Haslev, Denmark. lhvid@ph.au.dk., Stenager E; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.; Department of Neurology, MS-Clinic of Southern Jutland (Sønderborg, Esbjerg, Kolding), Sønderborg, Denmark., Dalgas U; Exercise Biology, Department of Public Health, Aarhus University, Dalgas Avenue 4, Aarhus, Denmark.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2022 Sep; Vol. 269 (9), pp. 4895-4908. Date of Electronic Publication: 2022 Apr 28.
DOI: 10.1007/s00415-022-11134-7
Abstrakt: Introduction: In persons with multiple sclerosis (pwMS), little evidence exist on the effects of Alemtuzumab on physiological, physical, and cognitive function along with patient-reported outcomes, despite these domains are being rated as highly important. Therefore, our purpose was to perform a prospective observational study to examine these outlined outcomes during the first two years of Alemtuzumab treatment in pwMS.
Methods: In n = 17 relapsing-remitting pwMS, physiological function [body composition; bone mineral content; muscle strength; aerobic capacity], physical function [6-min walk test (6MWT, primary outcome); timed 25 ft walk test (T25FWT); six spot step test (SSST); 9-step stair ascend (9SSA); timed up and go test (TUG); 5 × sit to stand test (5STS)], cognitive function [selective reminding test (SRT); symbol digit modalities test (SDMT)], and patient-reported outcomes [multiple sclerosis impact scale-29 (MSIS29); 12-item multiple sclerosis walking scale (MSWS12); modified fatigue impact scale (MFIS); hospital anxiety and depression scale (HADS)] were assessed prior to Alemtuzumab treatment initiation as well as 3, 6, 12, and 24 months into the treatment.
Results: Improvements were observed at 24-month follow-up in T25FWT (+ 8%), SSST (+ 10%), SDMT (+ 5.2 points, 53% improved more than the clinical cut-off score) and SRT, whereas the primary outcome 6MWT, and all other remaining outcomes, remained stable throughout the Alemtuzumab treatment period.
Conclusion: The present findings suggest that Alemtuzumab treatment in relapsing-remitting pwMS can improve certain domains of physical function (short distance walking) and cognitive function (processing speed, memory), and furthermore stabilize physiological and physical function along with patient-reported outcomes.
Trial Registration: Registered at clinicaltrials.gov: NCT03806387.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)
Databáze: MEDLINE
Externí odkaz: